liothyronine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1585 6893-02-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • liothyronine
  • liothyronine sodium
  • triiodothyronine
  • liothyronin
A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
  • Molecular weight: 650.98
  • Formula: C15H12I3NO4
  • CLOGP: 2.63
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 3
  • TPSA: 92.78
  • ALOGS: -4.52
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mcg O
60 mcg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 8, 1956 FDA KING PHARMS R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthyroidism 98.45 33.34 18 219 2079 2355769
Hypothyroidism 73.52 33.34 16 221 4441 2353407
Palpitations 66.02 33.34 19 218 16437 2341411
Drug ineffective 64.98 33.34 30 207 101594 2256254
Feeling abnormal 59.28 33.34 19 218 23562 2334286
Completed suicide 53.02 33.34 17 220 21017 2336831
Product substitution issue 50.06 33.34 12 225 5057 2352791
Alopecia 48.20 33.34 16 221 21985 2335863
Fatigue 44.56 33.34 22 215 84851 2272997
Malaise 43.40 33.34 19 218 55566 2302282
Product quality issue 41.03 33.34 12 225 10817 2347031
Thyroid function test abnormal 40.18 33.34 7 230 600 2357248
Weight increased 40.08 33.34 14 223 22323 2335525
Rhinovirus infection 37.51 33.34 6 231 305 2357543
Urticaria 35.20 33.34 13 224 24248 2333600
Acute respiratory distress syndrome 33.52 33.34 8 229 3284 2354564

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC H03AA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
ATC H03AA03 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
FDA EPC N0000175946 l-Triiodothyronine
FDA CS M0021977 Triiodothyronine

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Goiter indication 3716002 DOID:12176
Myxedema coma indication 21263006
Hypothyroidism indication 40930008 DOID:1459
Myxedema indication 43153006 DOID:11634
Congenital hypothyroidism indication 190268003 DOID:0050328
Simple goiter indication 267369002
Malignant tumor of thyroid gland indication 363478007 DOID:1781
T3 Suppression for Thyroid Function Test indication
Mild Hypothyroidism indication
Diagnostic Test for Thyroid Dysfunction indication
Myocardial infarction contraindication 22298006 DOID:5844
Thyrotoxic crisis contraindication 29028009 DOID:12837
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Osteoporosis contraindication 64859006 DOID:11476
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Angina pectoris contraindication 194828000
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Disorder of coronary artery contraindication 414024009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.08 acidic
pKa2 8.12 acidic
pKa3 8.77 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Thyroid hormone receptor alpha Nuclear hormone receptor AGONIST Kd 10.24 CHEMBL CHEMBL
Thyroid hormone receptor beta Nuclear hormone receptor AGONIST Ki 10.10 CHEMBL CHEMBL
THAP domain-containing protein 1 Unclassified EC50 9 WOMBAT-PK
Proliferating cell nuclear antigen Unclassified IC50 5.44 CHEMBL
GABA-A receptor; anion channel Ion channel IC50 4.64 CHEMBL
Adenosine receptor A1 GPCR Ki 6.62 DRUG MATRIX
Cytochrome P450 2C9 Enzyme EC50 6.30 WOMBAT-PK
GABA-A receptor; anion channel Ion channel EC50 5.15 CHEMBL
Thyroid hormone receptor beta Transcription factor IC50 8.74 CHEMBL

External reference:

IDSource
4022167 VUID
N0000020173 NUI
C0041014 UMLSCUI
D01011 KEGG_DRUG
06LU7C9H1V UNII
653 INN_ID
61275002 SNOMEDCT_US
350358003 SNOMEDCT_US
4022167 VANDF
d00658 MMSL
004882 NDDF
10814 RXNORM
CHEMBL1544 ChEMBL_ID
DB00279 DRUGBANK_ID
55-06-1 SECONDARY_CAS_RN
T3 PDB_CHEM_ID
CHEBI:18258 CHEBI
CHEMBL1201119 ChEMBL_ID
D014284 MESH_DESCRIPTOR_UI
5920 PUBCHEM_CID
2634 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 16590-303 TABLET 50 1 ORAL ANDA 13 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 33261-964 TABLET 5 ug ORAL ANDA 12 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 39822-0151 INJECTION, SOLUTION 10 ug INTRAVENOUS ANDA 12 sections
Triostat HUMAN PRESCRIPTION DRUG LABEL 1 42023-120 INJECTION 10 ug INTRAVENOUS NDA 12 sections
NP Thyroid 15 HUMAN PRESCRIPTION DRUG LABEL 2 42192-327 TABLET 2.25 ug ORAL unapproved drug other 21 sections
NP Thyroid 120 HUMAN PRESCRIPTION DRUG LABEL 2 42192-328 TABLET 18 ug ORAL unapproved drug other 21 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 42192-329 TABLET 4.50 ug ORAL unapproved drug other 21 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 42192-330 TABLET 9 ug ORAL unapproved drug other 21 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 42192-331 TABLET 13.50 ug ORAL unapproved drug other 21 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-417 TABLET 5 ug ORAL ANDA 18 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-418 TABLET 25 ug ORAL ANDA 18 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-419 TABLET 50 ug ORAL ANDA 18 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-018 TABLET 5 ug ORAL ANDA 18 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-019 TABLET 25 ug ORAL ANDA 18 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-020 TABLET 50 ug ORAL ANDA 18 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43063-884 TABLET 25 ug ORAL ANDA 18 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 45865-566 TABLET 9 ug ORAL unapproved drug other 21 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-3131 TABLET 5 ug ORAL ANDA 19 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 50090-4376 TABLET 4.50 ug ORAL unapproved drug other 22 sections
LIOTHYRONINE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 51655-122 TABLET 50 ug ORAL ANDA 11 sections
NP THYROID 90 HUMAN PRESCRIPTION DRUG LABEL 2 51655-124 TABLET 13.50 ug ORAL unapproved drug other 19 sections
NP THYROID 60 HUMAN PRESCRIPTION DRUG LABEL 2 51655-132 TABLET 9 ug ORAL unapproved drug other 17 sections
liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 51655-641 TABLET 25 ug ORAL ANDA 10 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 51862-320 TABLET 5 ug ORAL ANDA 18 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 51862-321 TABLET 25 ug ORAL ANDA 18 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 51862-322 TABLET 50 ug ORAL ANDA 18 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 53002-1029 TABLET 9 ug ORAL unapproved drug other 22 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 53002-1119 TABLET 4.50 ug ORAL unapproved drug other 22 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 53002-5800 TABLET 13.50 ug ORAL unapproved drug other 22 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 53217-361 TABLET 5 ug ORAL ANDA 12 sections